New classes of glaucoma medications

Current Opinion in Ophthalmology

Volumn 28, Issue 2, 2017, Pages 161-168

  Schehlein, Emily M ^a   Novack, Gary D ^b,c   Robin, Alan L ^a,d,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b PHARMALOGIC DEVELOPMENT INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

drug delivery; glaucoma; medications

Indexed keywords

ANTIGLAUCOMA AGENT; BAMOSIRAN; CANNABINOID DERIVATIVE; DRUG PRESERVATIVE; LATANOPROST; LATANOPROST PLUS NETARSUDIL; LATANOPROSTENE BUNOD; NETARSUDIL; OMIDENEPAG ISOPROPYL; RIPASUDIL; TRABODENOSON; UNCLASSIFIED DRUG; ADENOSINE RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; DRUG COMBINATION; PROSTAGLANDIN F; PROSTAGLANDIN RECEPTOR; RHO KINASE; SMALL INTERFERING RNA;

DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MEDICATION COMPLIANCE; NONHUMAN; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TOPICAL TREATMENT; AGONISTS; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; INTRAOCULAR PRESSURE;

ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS F, SYNTHETIC; PURINERGIC P1 RECEPTOR AGONISTS; RECEPTORS, PROSTAGLANDIN; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING;

EID: 84994559705     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0000000000000346     Document Type: Review

References (71)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90:262-267.
2. Friedman DS, Jampel HD, Munoz B, West SK. The prevalence of open-Angle glaucoma among Blacks and Whites 73 years and older: The Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol 2006; 124:1625-1630.
3. Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol 2012; 96:614-618.
4. Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-Analysis. Ophthalmology 2014; 121:2081-2090.
5. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology 1999; 106:653-662.
6. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-Angle glaucoma. Arch Ophthalmol (Chicago, Ill 1960) 2002; 120:701-730.
7. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol 2007; 144:533-540.
8. Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005; 112:863-868.
9. Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma 2004; 13:130-136.
10. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (Chicago, Ill 1960) 2002; 120:1268-1279.
11. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130:429-440.
12. Bacharach J, Dubiner HB, Levy B, et al. Double-masked, randomized, doseresponse study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. Ophthalmology 2015; 122:302-307.
13. Lewis R a, Levy B, Ramirez N, et al. Fixed-dose combination of AR-13324 and latanoprost: A double-masked, 28-day, randomised, controlled study in patients with open-Angle glaucoma or ocular hypertension. Br J Ophthalmol 2016; 100:1016.
14. Wang R-F, Williamson JE, Kopczynski C, Serle JB. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma 2015; 24:51-54.
15. Kiel JW, Kopczynski CC. Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther 2015; 31:146-151.
16. Li G, Mukherjee D, Navarro I, et al. Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes. Eur J Pharmacol 2016; 787:20-31.
17. Isobe T, Mizuno K, Kaneko Y, et al. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Curr Eye Res 2014; 39:813-822.
18. Kaneko Y, Ohta M, Inoue T, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemms canal endothelial cells. Sci Rep 2016; 6:19640.
19. Tanihara H, Inoue T, Yamamoto T, et al. Phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol 2013; 131:1288-1295.
20. Tanihara H, Inoue T, Yamamoto T, et al. Phase 2 randomized clinical study of a Rho kinase inhibitor, K-115, in primary open-Angle glaucoma and ocular hypertension. Am J Ophthalmol 2013; 156:731-736.
21. Okumura N, Okazaki Y, Inoue R, et al. Rho-Associated kinase inhibitor eye drop (Ripasudil) transiently alters the morphology of corneal endothelial cells. Invest Ophthalmol Vis Sci 2015; 56:7560-7567.
22. Tanihara H, Inoue T, Yamamoto T, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor Ripasudil (K-115) combined with timolol or latanoprost: A report of 2 randomized clinical trials. JAMA Ophthalmol 2015; 133:755-761.
23. Yamamoto K, Maruyama K, Himori N, et al. The novel Rho kinase (ROCK) inhibitor K-115: A new candidate drug for neuroprotective treatment in glaucoma. Invest Ophthalmol Vis Sci 2014; 55:7126-7136.
24. Sturdivant JM, Royalty SM, Lin C-W, et al. Discovery of the ROCK inhibitor netarsudil for the treatment of open-Angle glaucoma. Bioorg Med Chem Lett 2016; 26:2475-2480.
25. Levy B, Ramirez N, Novack GD, Kopczynski C. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol 2015; 159:980-985.
26. Katz JL, Weiss MJ, Heah T, et al. Two Phase 3 studies of the efficacy and safety of AR-13324 Ophthalmic Solution 0. 02%: in Patients with Open Angle Glaucoma and Ocular Hypertension. Seattle, WA: Paper session presented at: Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO); 2016.
27. Cavet ME, Vollmer TR, Harrington KL, et al. Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Invest Ophthalmol Vis Sci 2015; 56:4108-4116.
28. Medeiros FA, Martin KR, Peace J, et al. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-Angle glaucoma or ocular hypertension: The LUNAR Study. Am J Ophthalmol 2016; 168:250-259.
29. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene Bunod 0.024% versus timolol maleate 0.5% in subjects with open-Angle glaucoma or ocular hypertension: The APOLLO Study. Ophthalmology 2016; 123:965-973.
30. Weinreb RN, Ong T, Scassellati Sforzolini B, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: The VOYAGER study. Br J Ophthalmol 2015; 99:738-745.
31. Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res 1997; 64:979-989.
32. Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest Ophthalmol Vis Sci 2005; 46:3795-3799.
33. Laties A, Rich CC, Stoltz R, et al. A randomized phase 1 dose escalation study to evaluate safety, tolerability, and pharmacokinetics of trabodenoson in healthy adult volunteers. J Ocul Pharmacol Ther 2016; 32:548-554.
34. Myers JS, Sall KN, DuBiner H, et al. A dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of 2 and 4 weeks of twice-daily ocular trabodenoson in adults with ocular hypertension or primary open-Angle glaucoma. J Ocul Pharmacol Ther 2016; 32:555-562.
35. Ghaffarieh A, Lieven CJ, Levin LA, McVicar WK. Evaluation of the neuroprotective effects of trabodenoson in a model of acute ocular hypertension. Invest Ophthalmol Vis Sci 2014; 55:2427.
36. Ota T, Aihara M, Saeki T, et al. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest Ophthalmol Vis Sci 2006; 47:3395.
37. Wang JW, Woodward DF, Stamer WD. Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow. Invest Ophthalmol Vis Sci 2013; 54:4782-4790.
38. Nilsson SFE, Drecoll E, Lutjen-Drecoll E, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci 2006; 47:4042-4049.
39. Kalouche G, Beguier F, Bakria M, et al. Activation of prostaglandin FP and EP2 receptors differently modulates myofibroblast transition in a model of adult primary human trabecular meshwork cells. Invest Ophthalmol Vis Sci 2016; 57:1816-1825.
40. Ihekoromadu N, Lu F, Iwamura R, et al. Safety and efficacy of DE-117, a selective EP2 agonist in a Phase 2a study. Invest Ophthalmol Vis Sci 2015; 56:5708.
41. Yamane S, Karakawa T, Nakayama S, et al. IOP-lowering effect of ONO-9054, a novel dual agonist of prostanoid EP3 and FP receptors, in monkeys. Invest Ophthalmol Vis Sci 2015; 56:2547-2552.
42. Suto F, Rowe-Rendleman CL, Ouchi T, et al. A novel dual agonist of EP3 and FP Receptors for OAG and OHT: safety, pharmacokinetics, and pharmacodynamics of ONO-9054 in healthy volunteers. Invest Ophthalmol Vis Sci 2015; 56:7963-7970.
43. Harris A, Ward CL, Rowe-Rendleman CL, et al. Ocular hypotensive effect of ONO-9054, an EP3/FP receptor agonist: results of a randomized, placebocontrolled, dose escalation study. J Glaucoma 2016; 25:e826-e833.
44. Berlin MS, Rowe-Rendleman C, Ahmed I, et al. EP3/FP dual receptor agonist ONO-9054 administered morning or evening to patients with open-Angle glaucoma or ocular hypertension: results of a randomised crossover study. Br J Ophthalmol 2016; 100:843-847.
45. Miller-Ellis EG, Berlin MS, Ward CL, et al. Ocular hypotensive effects and tolerability of the novel dual EP3/FP receptor agonist ONO-9054 vs. Xalatan1: results of a 28 day, double masked, randomized, active comparator study in open angle glaucoma (OAG) and ocular hypertension (OHT). Seattle, WA: Paper session presented at: Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO); 2016.
46. Martinez T, Jimenez AI, Paneda C. Short-interference RNAs: becoming medicines. EXCLI J 2015; 14:714-746.
47. Martinez T, Gonzalez MV, Roehl I, et al. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther 2014; 22:81-91.
48. Moreno-Montanes J, Sadaba B, Ruz V, et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-Adrenergic receptor 2, for lowering intraocular pressure. Mol Ther 2014; 22:226-232.
49. Gonzalez V, Moreno-Montanes J, Oll M, et al. Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma. Seattle, WA: Poster session presented at: Annual Meeting of The Association for Research in Vision and Ophthalmology (ARVO); 2016.
50. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002; 86:418-423.
51. Zimmerman TJ, Hahn SR, Gelb L, et al. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence. J Ocul Pharmacol Ther 2009; 25:145-152.
52. Stone JL, Robin AL, Novack GD, et al. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol (Chicago, Ill 1960) 2009; 127:732-736.
53. Hennessy AL, Katz J, Covert D, et al. A video study of drop instillation in both glaucoma and retina patients with visual impairment. Am J Ophthalmol 2011; 152:982-988.
54. Hennessy AL, Katz J, Covert D, et al. Videotaped evaluation of eyedrop instillation in glaucoma patients with visual impairment or moderate to severe visual field loss. Ophthalmology 2010; 117:2345-2352.
55. Lewis R, Christie WC, Day DG, et al. Bimatoprost sustained-release implants for glaucoma therapy: interim results from a 24-month phase 1/2 clinical trial. Las Vegas, NV: Paper session presented at: The AAO Annual Meeting; 2015.
56. U.S. National Institutes of Health Clinical Trials. A Parallel-Arm, Randomized, Dose-Ranging Study of ENV515 Travoprost Extended-Release (XR) in Subjects With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma. NCT02371746 n.d. https://clinicaltrials.gov/ct2/show/NCT02371746.
57. Perera SA, Ting DS, Nongpiur ME, et al. Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population. Clin Ophthalmol 2016; 10:757-764.
58. Brandt JD, Sall K, DuBiner H, et al. Six-month intraocular pressure reduction with a topical bimatoprost ocular insert: results of a phase II randomized controlled study. Ophthalmology 2016; 123:1685-1694.
59. Allergan Inc. Lumigan (bimatoprost ophthalmic solution) 0.01%. Full prescribing information. n.d. http://www.allergan.com/assets/pdf/lumigan-pi.pdf [Accessed 6 May 2016].
60. Belyea DA, Alhabshan R, Del Rio-Gonzalez AM, et al. Marijuana use among patients with glaucoma in a city with legalized medical marijuana use. JAMA Ophthalmol 2016; 134:259-264.
61. Jampel H. American glaucoma society position statement: marijuana and the treatment of glaucoma. J Glaucoma 2010; 19:75-76.
62. Novack GD. Cannabinoids for treatment of glaucoma. Curr Opin Ophthalmol 2016; 27:146-150.
63. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol 2008; 53(Suppl 1):S57-S68.
64. Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: A cross-sectional survey. Ophthalmology 2015; 122:1308-1316.
65. Carpenter DM, Sayner R, Blalock SJ, et al. The effect of eye drop technique education in patients with glaucoma. Health Commun 2016; 31:1036-1042.
66. Lazcano-Gomez G, Castillejos A, Kahook M, et al. Videographic assessment of glaucoma drop instillation. J Curr Glaucoma Pract 2015; 9:47-50.
67. Carpenter DM, Blalock SJ, Sayner R, et al. Communication predicts medication self-efficacy in glaucoma patients. Optom Vis Sci 2016; 93:731-737.
68. Sleath B, Blalock SJ, Carpenter DM, et al. Ophthalmologist-patient communication, self-efficacy, and glaucoma medication adherence. Ophthalmology 2015; 122:748-754.
69. Blumberg DM, Prager AJ, Liebmann JM. Variation in prescription drug coverage enrollment among vulnerable beneficiaries with glaucoma before and after the implementation of Medicare Part D. JAMA Ophthalmol 2016; 134:212-220.
70. Blumberg DM, Prager AJ, Liebmann JM, et al. Cost-related medication nonadherence and cost-saving behaviors among patients with glaucoma before and after the implementation of Medicare Part D. JAMA Ophthalmol 2015; 133:985-996.
71. Novack GD. Time to take your medicines, seriously. Ocul Surf 2016; 14:410-415.